These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37060587)

  • 21. [Use of antidepressant drugs in schizophrenic patients with depression].
    Micallef J; Fakra E; Blin O
    Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiherpes virus-specific treatment and cognition in schizophrenia: a test-of-concept randomized double-blind placebo-controlled trial.
    Prasad KM; Eack SM; Keshavan MS; Yolken RH; Iyengar S; Nimgaonkar VL
    Schizophr Bull; 2013 Jul; 39(4):857-66. PubMed ID: 22446565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.
    Howard R; Cort E; Bradley R; Harper E; Kelly L; Bentham P; Ritchie C; Reeves S; Fawzi W; Livingston G; Sommerlad A; Oomman S; Nazir E; Nilforooshan R; Barber R; Fox C; Macharouthu A; Ramachandra P; Pattan V; Sykes J; Curran V; Katona C; Dening T; Knapp M; Romeo R; Gray R
    Health Technol Assess; 2018 Nov; 22(67):1-62. PubMed ID: 30507375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiglucocorticoid and related treatments for psychosis.
    Garner B; Phillips LJ; Bendall S; Hetrick SE
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD006995. PubMed ID: 26725721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2).
    Lennox B; Yeeles K; Jones PB; Zandi M; Joyce E; Yu LM; Tomei G; Pollard R; Vincent SA; Shimazaki M; Cairns I; Dowling F; Kabir T; Barnes TRE; Lingford Hughes A; Hosseini AA; Harrower T; Buckley C; Coles A
    Trials; 2019 Jun; 20(1):331. PubMed ID: 31174586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of non-schizophrenic disorders: focus on atypical antipsychotics.
    Jeste DV; Dolder CR
    J Psychiatr Res; 2004 Jan; 38(1):73-103. PubMed ID: 14690772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
    Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
    Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia.
    Girgis RR; Ciarleglio A; Choo T; Haynes G; Bathon JM; Cremers S; Kantrowitz JT; Lieberman JA; Brown AS
    Neuropsychopharmacology; 2018 May; 43(6):1317-1323. PubMed ID: 29090685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.
    Saavedra-Velez C; Yusim A; Anbarasan D; Lindenmayer JP
    J Clin Psychiatry; 2009 Jan; 70(1):104-12. PubMed ID: 19026265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
    Correll CU; Kohegyi E; Zhao C; Baker RA; McQuade R; Salzman PM; Sanchez R; Nyilas M; Carson W
    J Am Acad Child Adolesc Psychiatry; 2017 Sep; 56(9):784-792. PubMed ID: 28838583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B cells as therapeutic targets for rheumatic diseases.
    Looney RJ; Anolik J; Sanz I
    Curr Opin Rheumatol; 2004 May; 16(3):180-5. PubMed ID: 15103242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
    Barnes TR; Leeson VC; Paton C; Costelloe C; Simon J; Kiss N; Osborn D; Killaspy H; Craig TK; Lewis S; Keown P; Ismail S; Crawford M; Baldwin D; Lewis G; Geddes J; Kumar M; Pathak R; Taylor S
    Health Technol Assess; 2016 Apr; 20(29):1-46. PubMed ID: 27094189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.